136 related articles for article (PubMed ID: 15858615)
1. Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs.
Kumar S; Raje N; Hideshima T; Ishitsuka K; Roccaro A; Shiraishi N; Hamasaki M; Yasui H; Munshi NC; Richardson P; Figg WD; Anderson KC
Leukemia; 2005 Jul; 19(7):1253-61. PubMed ID: 15858615
[TBL] [Abstract][Full Text] [Related]
2. Etodolac induces apoptosis and inhibits cell adhesion to bone marrow stromal cells in human myeloma cells.
Nakamura S; Kobayashi M; Shibata K; Sahara N; Shigeno K; Shinjo K; Naito K; Hayashi H; Ohnishi K
Leuk Res; 2006 Feb; 30(2):123-35. PubMed ID: 16046235
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide for the treatment of multiple myeloma.
Hattori Y; Iguchi T
Congenit Anom (Kyoto); 2004 Sep; 44(3):125-36. PubMed ID: 15327481
[TBL] [Abstract][Full Text] [Related]
4. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
5. Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells.
Warfel NA; Lepper ER; Zhang C; Figg WD; Dennis PA
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3502-9. PubMed ID: 16740776
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.
Hideshima T; Chauhan D; Hayashi T; Podar K; Akiyama M; Mitsiades C; MItsiades N; Gong B; Bonham L; de Vries P; Munshi N; Richardson PG; Singer JW; Anderson KC
Cancer Res; 2003 Dec; 63(23):8428-36. PubMed ID: 14679006
[TBL] [Abstract][Full Text] [Related]
7. [Influence of thalidomide on bone marrow microenvironment in refractory and relapsed multiple myeloma].
Li J; Luo SK; Hong WD; Zhou ZH; Zou WY
Ai Zheng; 2003 Apr; 22(4):346-9. PubMed ID: 12703985
[TBL] [Abstract][Full Text] [Related]
8. Novel tubulin-polymerization inhibitor derived from thalidomide directly induces apoptosis in human multiple myeloma cells: possible anti-myeloma mechanism of thalidomide.
Iguchi T; Yachide-Noguchi T; Hashimoto Y; Nakazato S; Sagawa M; Ikeda Y; Kizaki M
Int J Mol Med; 2008 Feb; 21(2):163-8. PubMed ID: 18204782
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma.
van der Spek E; Bloem AC; Lokhorst HM; van Kessel B; Bogers-Boer L; van de Donk NW
Leuk Res; 2009 Jan; 33(1):100-8. PubMed ID: 18621417
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice.
Ng SS; MacPherson GR; Gütschow M; Eger K; Figg WD
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4192-7. PubMed ID: 15217957
[TBL] [Abstract][Full Text] [Related]
11. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
Yasui H; Hideshima T; Raje N; Roccaro AM; Shiraishi N; Kumar S; Hamasaki M; Ishitsuka K; Tai YT; Podar K; Catley L; Mitsiades CS; Richardson PG; Albert R; Brinkmann V; Chauhan D; Anderson KC
Cancer Res; 2005 Aug; 65(16):7478-84. PubMed ID: 16103102
[TBL] [Abstract][Full Text] [Related]
12. Novel therapies targeting the myeloma cell and its bone marrow microenvironment.
Hideshima T; Chauhan D; Podar K; Schlossman RL; Richardson P; Anderson KC
Semin Oncol; 2001 Dec; 28(6):607-12. PubMed ID: 11740818
[TBL] [Abstract][Full Text] [Related]
13. Antimyeloma effects of a sesquiterpene lactone parthenolide.
Suvannasankha A; Crean CD; Shanmugam R; Farag SS; Abonour R; Boswell HS; Nakshatri H
Clin Cancer Res; 2008 Mar; 14(6):1814-22. PubMed ID: 18347184
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
Anderson KC
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S3-8. PubMed ID: 16344099
[TBL] [Abstract][Full Text] [Related]
15. S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice.
Lentzsch S; Rogers MS; LeBlanc R; Birsner AE; Shah JH; Treston AM; Anderson KC; D'Amato RJ
Cancer Res; 2002 Apr; 62(8):2300-5. PubMed ID: 11956087
[TBL] [Abstract][Full Text] [Related]
16. Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells.
Ramasamy K; Khatun H; Macpherson L; Caley MP; Sturge J; Mufti GJ; Schey SA; Calle Y
Br J Haematol; 2012 Jun; 157(5):564-79. PubMed ID: 22428569
[TBL] [Abstract][Full Text] [Related]
17. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.
Monaghan KA; Khong T; Burns CJ; Spencer A
Leukemia; 2011 Dec; 25(12):1891-9. PubMed ID: 21788946
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy.
Scullen T; Santo L; Vallet S; Fulciniti M; Eda H; Cirstea D; Patel K; Nemani N; Yee A; Mahindra A; Raje N
Leukemia; 2013 Aug; 27(8):1715-21. PubMed ID: 23417027
[TBL] [Abstract][Full Text] [Related]
19. Molecular target characterization and antimyeloma activity of the novel, insulin-like growth factor 1 receptor inhibitor, GTx-134.
Liang SB; Yang XZ; Trieu Y; Li Z; Zive J; Leung-Hagesteijn C; Wei E; Zozulya S; Coss CC; Dalton JT; Fantus IG; Trudel S
Clin Cancer Res; 2011 Jul; 17(14):4693-704. PubMed ID: 21632854
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis.
Du GJ; Lin HH; Xu QT; Wang MW
Vascul Pharmacol; 2005 Aug; 43(2):112-9. PubMed ID: 15982930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
